US Pharm. 2008;33(7):HS-16. 

Attendees at a meeting of the American Association for Cancer Research learned that while the results of a study conducted at Rutgers University in New Brunswick, NJ, showed that atorva­ statin (Lipitor) and celecoxib (Celebrex) individually slowed tumor progression from androgen-dependent to androgen-independent status, the two drugs combined had additive growth-inhibiting activity compared with either drug alone.

According to Xi Zheng, PhD, of Rutgers, study results showed that the combination of the two drugs represented "a viable prevention strategy to stop the progression of prostate cancer to androgen-independent status, which is more aggressive and currently has limited therapeutic options."

To comment on this article, contact